Results 101 to 110 of about 11,287 (253)

Does perceived stigma impact opioid use disorder treatment uptake? A cross-sectional secondary analysis of buprenorphine engagement among syringe service program participants

Addiction Science & Clinical Practice
Introduction Buprenorphine is an effective medication for opioid use disorder (OUD) treatment; however, stigma surrounding substance use may deter individuals from seeking treatment and contribute to lower engagement once treatment is initiated.
Bailey Campbell, Lindsey R. Riback, Juan Gatica Portillo, Stephanie Maricic, Aaron D. Fox   +4 more
doaj   +1 more source

Methadone or buprenorphine? The choice of substitution therapy in pregnant opioid dependent women

, 2019
Pregnant opioid dependent women have an increased risk of complications both during pregnancy and delivery. Substitution therapy can considerably reduce this risk.
Jadwiga Zalewska-Kaszubska
core   +1 more source

Efficacy and safety of pharmacological interventions for the treatment of cocaine use disorder: A systematic review and network meta‐analysis

Addiction, EarlyView.
Abstract Background and aims Cocaine use disorder (CUD) is an increasingly widespread concern worldwide. Various pharmacological treatments have been investigated for CUD, but their efficacy remains unclear, and none have been licensed for treatment.
Craig Paterson, Thomas Parkhouse, Chloe Burke, Monika Halicka, Jennifer C. Palmer, Hend Gabr, Rebecca Wilson, Katie E. Webster, Francesca Spiga, Sarah Dawson, Deborah M. Caldwell, Jennifer Scott, Julian P. T. Higgins, Jelena Savović   +13 more
wiley   +1 more source

Buprenorphine, methadone, and morphine treatment during pregnancy: behavioral effects on the offspring in rats

, 2015
Hwei-Hsien Chen,1,2,* Yao-Chang Chiang,3,4,* Zung Fan Yuan,5,6 Chung-Chih Kuo,5,6 Mei-Dan Lai,2 Tsai-Wei Hung,1 Ing-kang Ho,1,3,4 Shao-Tsu Chen2,7 1Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli County, Taiwan; 2Master
Chiang YC, Ho IK, Kuo CC, Lai MD, Yuan ZF, Hung TW, Chen ST, Chen HH   +7 more
core  

Practice guidelines for the administration of buprenorphine for treating opioid use disorder.

, 2021
The Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder provides eligible US physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, and ...

core  

Craving and personal functioning as mediators of extended‐release buprenorphine efficacy: A four‐way decomposition analysis from a randomised trial

Addiction, EarlyView.
Abstract Aims To investigate whether the treatment effect of extended‐release buprenorphine (BUP‐XR) on opioid‐free days in opioid use disorder (OUD) is mediated by reductions in opioid craving and improvements in personal functioning. Design and setting Exploratory causal mediation analysis using VanderWeele's four‐way decomposition framework in a 24 ...
John Marsden, Mike Kelleher, Fiona Cowden, Edward Day, Jonathan Dewhurst, Rachel Evans, Eilish Gilvarry, Natalie Lowry, Luke Mitcheson, Robert Murray, Sophie Quarshie, Zoë Hoare   +11 more
wiley   +1 more source

Predicting buprenorphine adherence among patients with opioid use disorder in primary care settings

BMC Primary Care
Background Medications for opioid use disorder (MOUD), including buprenorphine, are effective treatments for opioid use disorder (OUD) and reduce risk for overdose and death.
Stephanie A. Hooker, Colleen Starkey, Gavin Bart, Rebecca C. Rossom, Sheryl Kane, Anthony W. Olson   +5 more
doaj   +1 more source

Overdose reversal through peer intervention: Findings from the naloxone prospective outcome research study (NalPORS) on the effectiveness of overdose response by people who use opioids in the United Kingdom and Sweden

Addiction, EarlyView.
Abstract Background/aims Take‐home naloxone (THN) programmes have been introduced in many European countries to provide non‐medically trained people who are likely to witness an opioid overdose, including people who use opioids, with a naloxone kit and training.
Nicola Metrebian, Teodora Dascal, Clare Mackie, Rose Tinch‐Taylor, Ben Carter, Joanne Neale, Mariana Gonzalez Utrilla, Ed Day, Joar Guterstam, Kirsten Horsburgh, Martin Kåberg, Mike Kelleher, Soraya Mayet, Josie Smith, Desiree Eide, Elin Holmén, Rebecca McDonald, Stephen Parkin, Henrik Thiesen, John Strang, NalPORS Research Team, Dean Acreman, Shabana Akhtar, Louise Aitken, Martin Anderson, James Cassidy, Sarah Cosgrove, Jo Grayer, Michelle Hughes, Louise Horn, Anika Miah, John Pratt   +31 more
wiley   +1 more source

Advances in the delivery of buprenorphine for opioid dependence

, 2017
Richard N Rosenthal,1 Viral V Goradia2 1Department of Psychiatry, Addiction Institute at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, 2Department of Psychiatry, Upstate Medical University, Syracuse, NY, USA Abstract: Opioid use ...
Rosenthal RN, Goradia VV
core  

Real‐world comparative effects of slow‐release oral morphine vs. methadone on healthcare use for opioid use disorder: A population‐based target trial emulation

Addiction, EarlyView.
Abstract Aims To examine the comparative effects of slow‐release oral morphine (SROM) vs. methadone for the treatment of opioid use disorder (OUD) on healthcare use. Design This retrospective cohort study emulated a target trial using electronic medical record data from Vancouver Coastal Health Authority linked with population‐based administrative ...
Vivienne Y. Zhou, Nadia Fairbairn, Jingxin Lei, Rupinder Brar, Paxton Bach, M. Eugenia Socias   +5 more
wiley   +1 more source